阿联酋糖尿病患者心衰的管理:行动呼吁。

IF 2.5 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Journal of Cardiovascular Pharmacology and Therapeutics Pub Date : 2023-01-01 DOI:10.1177/10742484231162248
Hani Sabbour, Aftab Ahmad
{"title":"阿联酋糖尿病患者心衰的管理:行动呼吁。","authors":"Hani Sabbour,&nbsp;Aftab Ahmad","doi":"10.1177/10742484231162248","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) is an important adverse outcome of diabetes mellitus (DM) with high rates of mortality and HF-related hospitalizations. The risk of HF is 2 times higher in patients with DM compared to those without DM. Due to under-recognition and underdiagnoses, HF is often a neglected outcome in the diabetic population. There is a dearth of data regarding the true prevalence of HF and the management protocols for diabetic patients at risk of HF in the UAE and the Middle East. This lacuna in the information has led to the inception of this \"call to action\" paper, which identifies the gaps in the true prevalence of HF and describes the importance of early diagnosis and appropriate management of HF in the Middle East.</p><p><strong>Methodology: </strong>An advisory board meeting was convened and a group of key opinion leaders and experts in cardiology and endocrinology assembled to describe the prevalence, diagnosis, and management of HF in diabetes patients and to present a \"call to action\" in the UAE and Middle East scenario. After the group discussion, key expert opinions were formulated and \"call to action\" recommendations were proposed.</p><p><strong>Conclusion: </strong>This \"call to action\" is mainly based on the available evidence from the literature and the experts' clinical experience. Based on the new evidence from various cardiovascular outcome trials, the \"call to action\" highlights a series of collaborative learning regarding the role of newer antidiabetic therapies like sodium-glucose cotransporter-2 inhibitors in the prevention and management of HF. This \"call to action\" intends to serve as a guide for physicians, including primary healthcare providers, in their management of diabetic patients with HF.</p>","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"28 ","pages":"10742484231162248"},"PeriodicalIF":2.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Management of Heart Failure in Patients With Diabetes Mellitus in the UAE: A Call to Action.\",\"authors\":\"Hani Sabbour,&nbsp;Aftab Ahmad\",\"doi\":\"10.1177/10742484231162248\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Heart failure (HF) is an important adverse outcome of diabetes mellitus (DM) with high rates of mortality and HF-related hospitalizations. The risk of HF is 2 times higher in patients with DM compared to those without DM. Due to under-recognition and underdiagnoses, HF is often a neglected outcome in the diabetic population. There is a dearth of data regarding the true prevalence of HF and the management protocols for diabetic patients at risk of HF in the UAE and the Middle East. This lacuna in the information has led to the inception of this \\\"call to action\\\" paper, which identifies the gaps in the true prevalence of HF and describes the importance of early diagnosis and appropriate management of HF in the Middle East.</p><p><strong>Methodology: </strong>An advisory board meeting was convened and a group of key opinion leaders and experts in cardiology and endocrinology assembled to describe the prevalence, diagnosis, and management of HF in diabetes patients and to present a \\\"call to action\\\" in the UAE and Middle East scenario. After the group discussion, key expert opinions were formulated and \\\"call to action\\\" recommendations were proposed.</p><p><strong>Conclusion: </strong>This \\\"call to action\\\" is mainly based on the available evidence from the literature and the experts' clinical experience. Based on the new evidence from various cardiovascular outcome trials, the \\\"call to action\\\" highlights a series of collaborative learning regarding the role of newer antidiabetic therapies like sodium-glucose cotransporter-2 inhibitors in the prevention and management of HF. This \\\"call to action\\\" intends to serve as a guide for physicians, including primary healthcare providers, in their management of diabetic patients with HF.</p>\",\"PeriodicalId\":15281,\"journal\":{\"name\":\"Journal of Cardiovascular Pharmacology and Therapeutics\",\"volume\":\"28 \",\"pages\":\"10742484231162248\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cardiovascular Pharmacology and Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/10742484231162248\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Pharmacology and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10742484231162248","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:心力衰竭(HF)是糖尿病(DM)的一个重要不良结局,具有高死亡率和与HF相关的住院率。糖尿病患者发生心衰的风险是非糖尿病患者的2倍。由于对心衰的认识和诊断不足,心衰在糖尿病人群中经常被忽视。在阿联酋和中东地区,关于心衰的真实患病率和有心衰风险的糖尿病患者的管理方案的数据缺乏。这一信息上的空白导致了这份“行动呼吁”文件的开始,该文件确定了心力衰竭真实患病率方面的差距,并描述了早期诊断和适当管理心力衰竭在中东的重要性。方法:召开了一次咨询委员会会议,召集了一组心脏病学和内分泌学的主要意见领袖和专家,描述糖尿病患者心衰的患病率、诊断和管理,并在阿联酋和中东地区提出“行动呼吁”。小组讨论后,形成重点专家意见,提出“行动呼吁”建议。结论:这一“行动呼吁”主要基于现有的文献证据和专家的临床经验。基于来自各种心血管结局试验的新证据,“行动呼吁”强调了一系列关于新型抗糖尿病疗法(如钠-葡萄糖共转运蛋白-2抑制剂)在预防和管理心衰中的作用的协作学习。这一“行动呼吁”旨在作为医生,包括初级卫生保健提供者,在他们的糖尿病合并心衰患者的管理指南。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Management of Heart Failure in Patients With Diabetes Mellitus in the UAE: A Call to Action.

Background: Heart failure (HF) is an important adverse outcome of diabetes mellitus (DM) with high rates of mortality and HF-related hospitalizations. The risk of HF is 2 times higher in patients with DM compared to those without DM. Due to under-recognition and underdiagnoses, HF is often a neglected outcome in the diabetic population. There is a dearth of data regarding the true prevalence of HF and the management protocols for diabetic patients at risk of HF in the UAE and the Middle East. This lacuna in the information has led to the inception of this "call to action" paper, which identifies the gaps in the true prevalence of HF and describes the importance of early diagnosis and appropriate management of HF in the Middle East.

Methodology: An advisory board meeting was convened and a group of key opinion leaders and experts in cardiology and endocrinology assembled to describe the prevalence, diagnosis, and management of HF in diabetes patients and to present a "call to action" in the UAE and Middle East scenario. After the group discussion, key expert opinions were formulated and "call to action" recommendations were proposed.

Conclusion: This "call to action" is mainly based on the available evidence from the literature and the experts' clinical experience. Based on the new evidence from various cardiovascular outcome trials, the "call to action" highlights a series of collaborative learning regarding the role of newer antidiabetic therapies like sodium-glucose cotransporter-2 inhibitors in the prevention and management of HF. This "call to action" intends to serve as a guide for physicians, including primary healthcare providers, in their management of diabetic patients with HF.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.00
自引率
0.00%
发文量
33
审稿时长
6-12 weeks
期刊介绍: Journal of Cardiovascular Pharmacology and Therapeutics (JCPT) is a peer-reviewed journal that publishes original basic human studies, animal studies, and bench research with potential clinical application to cardiovascular pharmacology and therapeutics. Experimental studies focus on translational research. This journal is a member of the Committee on Publication Ethics (COPE).
期刊最新文献
The Role of JAK/STAT Signaling Pathway and Its Downstream Influencing Factors in the Treatment of Atherosclerosis Exposure to Electronic Waterpipes Increases the Risk of Occlusive Cardiovascular Disease in C57BL/6J Mice Thanks to Reviewers Prognostic Implications of Immature Platelet Fraction at 5-Year Follow-up Among ACS Patients Treated With Dual Antiplatelet Therapy. Assessment of Dofetilide or Sotalol Tolerability in the Elderly.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1